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Abstract
Background: A bundled approach to central venous catheter care is currently being promoted as an effective way of
preventing catheter-related bloodstream infection (CR-BSI). Consumables used in the bundled approach are relatively
inexpensive which may lead to the conclusion that the bundle is cost-effective. However, this fails to consider the nontrivial
costs of the monitoring and education activities required to implement the bundle, or that alternative strategies are
available to prevent CR-BSI. We evaluated the cost-effectiveness of a bundle to prevent CR-BSI in Australian intensive care
patients.
Methods and Findings: A Markov decision model was used to evaluate the cost-effectiveness of the bundle relative to
remaining with current practice (a non-bundled approach to catheter care and uncoated catheters), or use of antimicrobial
catheters. We assumed the bundle reduced relative risk of CR-BSI to 0.34. Given uncertainty about the cost of the bundle,
threshold analyses were used to determine the maximum cost at which the bundle remained cost-effective relative to the
other approaches to infection control. Sensitivity analyses explored how this threshold alters under different assumptions
about the economic value placed on bed-days and health benefits gained by preventing infection. If clinicians are prepared
to use antimicrobial catheters, the bundle is cost-effective if national 18-month implementation costs are below $1.1 million.
If antimicrobial catheters are not an option the bundle must cost less than $4.3 million. If decision makers are only interested
in obtaining cash-savings for the unit, and place no economic value on either the bed-days or the health benefits gained
through preventing infection, these cost thresholds are reduced by two-thirds.
Conclusions: A catheter care bundle has the potential to be cost-effective in the Australian intensive care setting. Rather
than anticipating cash-savings from this intervention, decision makers must be prepared to invest resources in infection
control to see efficiency improvements.
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Introduction
Catheter-related bloodstream infections (CR-BSIs) have been
shown to increase health costs and patient morbidity [1]. They are
thought to be more than 50% preventable [2] and have been the
target of initiatives to create safer and efficient healthcare systems
[3]. They are now included amongst the list of adverse events for
which, under the Deficit Reduction Act, United States hospitals
will no longer receive reimbursement [4]. This legislation created
an economic imperative for decision makers to identify cost-
effective infection control programmes [5]. The evidence for the
effectiveness of numerous single and multi-module interventions to
prevent CR-BSI has been reviewed [6,7] but there is a lack of
information about the cost-effectiveness of these activities [8].
An important intervention for which there is no economic
evidence is the ‘‘bundled’’ approach to CR-BSI prevention
promoted by the Institute for Health Improvement as part of
their 100k Lives Campaign [3] (www.ihi.org). Five simple
interventions that have strong scientific evidence for effectiveness
are combined and integrated into clinical practice as a ‘bundle’:
use of optimal hand hygiene, chlorhexidine skin antisepsis,
maximal barrier precautions for catheter insertion, choice of
optimal insertion site, and prompt catheter removal. Implemen-
tation involves monitoring practice compliance as well as infection
rates, along with healthcare worker education and development of
leadership in the area of infection control. This bundle [3] is
currently being promoted for use in several countries including
Australia. Studies indicate that this bundle is highly effective, with
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some settings reducing and maintaining their infection rates at
zero [9,10].
The cost-effectiveness of the bundle compared to other infection
control interventions is currently not known. Each individual
component of the bundle is relatively inexpensive to implement.
This has led some clinical leaders to conclude that the bundle will
be cost-effective. However, these statements do not appear to
consider the nontrivial costs of monitoring and the education
activities required to implement a bundled approach in a new
setting. These activities require significant time and resources at
the outset of the intervention and at recurrent intervals and should
be included when undertaking an economic evaluation of this
approach.
An evaluation should also recognize other relevant interventions
to prevent CR-BSI that may need to be included in the decision.
There is strong evidence that antimicrobial central venous
catheters (A-CVCs) are effective at reducing risk of CR-BSI [11]
and the cost-effectiveness of these devices has been have been
assessed in the Australian context [12]. Some clinicians are
hesitant about their use, due to risk of potential side-effects
[13,14], and may not consider use of these devices an option.
However, for those clinicians whose preferences include the use, or
intended use of A-CVCs, they represent an additional relevant
alternative.
This study looks at the cost-effectiveness of a catheter care
bundle relative to current practice, defined as a non-bundled
approach to central line management with use of uncoated CVCs,
and to two types of A-CVC currently available to public hospitals
in Australia [15]: internally coated chlorhexidine/silver sulfadia-
zine (CH/SSD) catheters and minocycline and rifampicin (MR)
coated catheters. This provides the first data about the economic
conditions under which a catheter care bundle might be cost-
effective in the intensive care unit setting.
Methods
Ethics statement
Ethics approval for this research was granted by Queensland
University of Technology (0600000379) who waived written
patient consent as all data was sourced from pre-existing
databases, was provided in a de-identified form and was analyzed
anonymously.
Development of the economic model
The context for the evaluation was a Level III adult intensive
care unit (ICU) in an Australian public teaching hospital. Clinical
and economic events under a healthcare perspective were
identified in conjunction with intensive care clinicians and
organized into Markov states (Figure 1) to create an economic
decision model. This is the same model that has been used to
evaluate the cost-effectiveness of A-CVCs in this context [12]. All
models were built in Microsoft Excel.
Patients were assumed to receive a CVC on entry to ICU. Over
subsequent cycles the catheter was either retained, removed as no
longer necessary, or removed due to development of CR-BSI,
which was defined according to the clinical definition used by the
Centers for Disease Control and Prevention [6]. Patients faced an
underlying risk of mortality representative of being in ICU and an
elevated risk should they develop CR-BSI. The surviving cohort
was followed for the remainder of their lifetime. We did not model
catheter colonization as this event alone carries no health or
economic consequences. We assumed all catheters were inserted
or removed within the ICU and that there were no multiple
catheterizations. The consequences of CR-BSI were assumed to be
independent of patient age or disease severity and causative micro-
organisms. Economic costs were measured in 2006 Australian
dollars. Health outcomes were measured in quality-adjusted life
years (QALYs). A discount rate of 3% was applied to costs and
QALYs occurring in future time periods [16].
Data used in the model, its source and the level of this evidence
as judged by the modified version of the hierarchy of data sources
for economic evaluation [17] are shown in Table 1. Where
possible, estimates for epidemiological parameters were obtained
from the published literature using searches undertaken in
Medline from January 1985 to January 2008. Cost data was
sourced primarily from routine databases held by the Queensland
State and Australian Federal healthcare systems.
Based on a four year dataset of 11,790 ICU admissions we
assumed that 17% would receive a CVC (Mullaney D. Methods
and preliminary results for a data linkage project to determine
long-term survival after intensive care unit admission [abstract];
2008; Second International Conference on Quality Audit and
Outcomes Research in Intensive Care; Christchurch, New
Zealand). Our catheterised cohort had a mean age 62.7 (s.d.
17.2) years, mean Acute Physiology and Chronic Health
Evaluation II score 17.1 (s.d. 8) and were 65% male, equivalent
to admissions reported to 46 publicly funded ICUs by the
Australia New Zealand Intensive Care Society [18]. Baseline risk
of ICU mortality was 9.8% and 16.1% by hospital discharge.
Daily probabilities of catheter removal was estimated by fitting a
Weibull distribution to data from an epidemiological study of
7,467 CVCs [19] whilst daily probability of CR-BSI was modelled
as increasing, in stepwise increments, with duration of catheter-
isation [19]. This gave a probability of infection of 2.5%
comparable to that observed in routine surveillance data collected
from February 2001 to December 2005 in 21 medium-to-large
public hospitals in Queensland, Australia [20].
Relative risk of hospital mortality associated with CR-BSI was
estimated to be 1.06 [1]. Given a 9.8% baseline risk this
corresponds to an absolute increase in mortality just under 1%.
Excess length of stay due to infection was estimated at 2.4 ICU
and 7.5 general ward days [21]. Annual mortality rates for fifteen
years post-ICU discharge were taken from a data linkage study
[22] that followed over 10,000 Australian ICU patients.
Subsequent life expectancy was based on Australian Institute of
Health and Welfare published age-specific mortality rates [23].
Preference based utility weights from a study [24] with participant
demographics similar to our cohort were assigned to cycles spent
in the ICU and 6 months immediately post-discharge. No further
quality of life decrement was attributed to CR-BSI. As we did not
consider side effects for the interventions (negative or positive) we
did not incorporate these into the utility weightings. Although
evidence suggests that quality of life may be reduced in some
survivors for a longer period post-discharge [25], information on
this was unavailable for our population, so, to be conservative, life
expectancy for those surviving beyond this period were adjusted
using Australian population quality of life norms [26].
All costs were valued at 2006 prices, using the Bureau of Labor
Statistics Consumer Price Index [27] to adjust where necessary.
Consumable costs in the evaluation included the price of the
catheters, CR-BSI diagnosis costs (one catheter tip and two blood
cultures) and treatment costs. Treatment costs were a weighted
average of the cost of standard regimens for causative organisms
observed within the surveillance system: two weeks Vancomycin,
ten days Ticarcillin/clavulanate, four weeks Fluconazole. The cost
for all consumables reflected prices faced by Queensland Health
decision-makers. The economic value of bed-days released by the
prevention of CR-BSI was estimated based on their likely value to
Is a CVC Bundle Cost-Effective
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a Queensland Health decision-maker. Values for an ICU bed-day
were obtained from a detailed costing study of an Australian ICU
[28] and for a general ward bed-day from an earlier economic
evaluation which considered spending patterns for Australian
public hospital services [29]. These estimates of $3,021 and $843
represent short-run average costs calculated by dividing total costs
(i.e. fixed and variable costs) by the total bed days for a 12 month
budget period. It is unknown whether these accounting based costs
approximate the economic opportunity cost of the marginal bed
day.
Estimates for the effectiveness of each type of commercially
available A-CVC relative to uncoated catheters were taken from
the results of a meta-analysis which provided separate estimates of
effectiveness for each catheter type [11]. The additional cost of
each antimicrobial catheter type (relative to uncoated catheters)
was based on their cost on Standard Offer Arrangement with
Queensland Health. We assumed that there would be no other
costs associated with the introduction of antimicrobial catheters as
the mechanisms for procurement, storage and usage of these
catheters are identical to those used for uncoated catheters. To
estimate the total cost of each type of A-CVC over 18 months, we
estimated the total number of catheters that would be used during
this time, based on data reported to the Australia and New
Zealand Intensive Care Society 2003-05 resources and activity
report [18]; 46 of 47 eligible Australian Level III public ICUs
contributed data, reporting a total of 53,470 adult Level III ICU
admissions annually. Assuming 17% would receive a catheter
(Mullaney D. Methods and preliminary results for a data linkage
project to determine long-term survival after intensive care unit
admission [abstract]; 2008; Second International Conference on
Quality Audit and Outcomes Research in Intensive Care;
Christchurch, New Zealand), and making the simplifying assump-
tion that patients receive only one catheter, we predicted 13,635
catheterisations over an 18 month period.
Knowledge about the effectiveness and cost of a
catheter care bundle
A variety of bundled behavioural interventions to prevent CR-
BSI have been evaluated and reported in the scientific literature.
The quality of many of these studies is uncertain [30]. For this
evaluation we used estimates of the effectiveness of a bundle from
the study by Pronovost et. al. [31]. The intervention in this study
forms the basis for the catheter care and management bundle
advocated by the Institute for Health Improvement 100k Lives
Campaign [3] which is now being recommended for use in
Australia. The bundle was comprised of five elements: use of
Figure 1. Markov model used for the economic evaluation. Arrows represent possible pathways for patient movement through the Markov
model, circular arrows indicate the patient can remain in their current health state for subsequent cycles of the model, the small downward arrows
from each health state represent mortality. Transition probabilities are shown. Where * is used, transition probabilities vary over time. See Table One
for more details.
doi:10.1371/journal.pone.0012815.g001
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optimal hand hygiene, chlorhexidine skin antisepsis, maximal
barrier precautions for catheter insertion, choice of optimal
insertion site, and prompt catheter removal and kits containing
all the equipment recommended for catheter insertion were
created. Implementation included programs to educate staff about
clinical leadership, and infection risk as well as the bundle. The
intervention reduced the rate of CR-BSI from 7.7 to 1.4 per 1,000
line days over an 18 month period; a reduction in relative risk of
0.34 (95% CI 0.23, 0.50).
The costs of implementing the bundle fall into two groups. First
are those related to the five components. A list of the resources
required to implement these is given in Table 2. It is estimated that
the cost of these resources to Queensland Health decision-makers
would be minimal. The second group of resources are those
related to the monitoring, education and leadership activities.
Table 2 summarises the resources associated with these activities
based on descriptions provided across six publications produced
from the Pronovost et. al. study [9,31,32,33,34,35], but any
Table 1. Parameters used in the model.
Parameters Estimate Source Ref Level of evidence
Infection related events
Daily probability CR-BSI Day 1–5 0.004 database & Q–E study [22][21] 1
Day 6–15 0.009
Day 16–30 0.020
RR mortality CR-BSI 1.06 Q–E study [1] 2
Daily probability catheter removal time varying Q–E study [21] 2
Baseline mortality (probabilities)
ICU 0.098 data linkage study [24] 2
Hospital 0.069
Annual post-discharge Year 1 0.050
Year 2–3 0.027
Year 4–5 0.028
Year 6–10 0.037
Year 11–15 0.042
Underlying annual mortality 45–64 yrs 0.004 national statistics [25] 1
65–84 yrs 0.030
85+ yrs 0.140
Utilities
ICU 0.66 elicitation study (EQ-5D) [26] 3
Population norms 50–59 yrs 0.80 population based survey [28] 3
60–69 yrs 0.79
70–79 yrs 0.75
80+ yrs 0.66
Cost of CR-BSI
Extra days ICU 2.41 Q–E study [23] 2
ICU bed-day (2006 AUD) 3,021 costing study [30] 4
Extra days hospital 7.54 Q–E study [23] 2
Hospital bed-day (2006 AUD) 843 prior economic evaluation [31] 3
Diagnostics CR-BSI (2006 AUD) 101.7 health system database - 1
Treatment CR-BSI (2006 AUD) 591.3
Effectiveness infection control (RR)
CH/SSD catheter 0.66 meta-analysis [12] 1+
MR catheter 0.39
Bundle 0.34 Q–E study [33] 2
Additional cost infection control (per catheter; 2006 AUD)
CH/SSD catheter 11.64 health system database - 1
MR catheter 59.36
Bundle unknown - - 6
Abbreviations: s.e. standard error; CR-BSI catheter related bloodstream infection; ICU intensive care unit; Q–E quasi-experimental; AUD Australian dollar; ec. eval’n
economic evaluation; CH/SSD chlorhexidine & silver sulfadiazine; (int/ext) internal & external coating; SPC silver, platinum & carbon; MR minocycline & rifampicin;
popul’n population; per comm. personal communication; A-CVC antimicrobial central venous catheter; RR relative risk.
doi:10.1371/journal.pone.0012815.t001
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Table 2. Resources potentially required to implement a catheter care bundle.
Activity Resources
Unit Frequency
Catheter care bundle components
Components
Appropriate hand hygiene 30 seconds per catheter
Maximal sterile barrier precautions at insertion
mask, gloves, gown, cap, large drape 1 set per catheter
preparation of precautions 20 minutes per catheter
Chlorhexidine skin preparation 7 day supply per catheter
Subclavian vein placement preferred no additional activity
Prompt removal of catheters no additional activity
Central line supply care
Stocking of cart no data every 4 hours
Use of cart time saving per catheter
Education & monitoring activities
Education
Nurse lectures 40 minutes 16 lectures
Physician lectures 40 minutes 5 lectures
Web-based physician training module no data on duration or attendees no data on repetition
Nurse orientation module no data on duration or attendees no data on repetition
Posters & factsheets no data on numbers no data numbers
Checklist for insertion
Training on use no data on duration or attendees no data on repetition
Use of checklist 2 minutes per catheter
Feedback on performance no data on resources no data on repetition
Collation & feedback of infection rates no data on resources no data on repetition
Mentoring & leadership activities
Keystone project support*
Conference calls from Keystone no data on duration or attendees 2 per month
Conference calls from Hopkins no data on duration or attendees 1 per month
Statewide meetings no data on duration or attendees 2 per year
Participant website no data on resources no data on updates
Bimonthly e-newsletter no data on resources 2 per month
Institution visits no data on resources no data on repetition
Key personnel (average four) per hospital
Physician leader 4–8 hours per week
Nurse leader 4–8 hours per week
Senior executive 4–8 hours per week
Staff nurse/infection control practitioner/pharmacist 4–8 hours per week
Program activities
Education session & safety survey 40 minutes, all staff once
Senior executive meetings no data on duration or attendees 1 per month
Daily goals sheet for communication no data on resources 3 per day
Nurse pre-discharge medication review no data on resources per admission
Web-based error reporting system no data on resources no data on maintenance
*Keystone funded to $15 million to undertake multiple projects not just a catheter care bundle.
Resources were identified based on the following publications:
Pronovost PJ, Berenholtz S, Dorman T, Lipsett PA, Simmonds T, Haraden C: Improving communication in the ICU using daily goals. J Crit Care 2003, 18:71–75.
Pronovost PJ, Weast B, Bishop K, Paine L, Griffith R, Rosenstein B, Kidwell RP, Haller KB, Davis R: Senior executive adopt-a-work unit: a model for safety improvement. Jt
Comm J Qual Patient Saf 2004, 30:59–68.
Pronovost PJ, Goeschel C: Improving ICU care: it takes a team. Healthc Exec 2005, 20:15–22.
Pronovost PJ, Weast B, Rosenstein B, Sexton B, Holzmueller CG, Paine L, Davis R, Rubin HR: Implementing and validating a comprehensive unit-based safety program.
Journal of Patient Safety 2005, 1:33–40.
Pronovost PJ, Needham DM, Berenholtz S, Sinopoli D, Chu H, Cosgrove SE, Sexton B, Hyzy R, Welsh R, Roth G, Bander J, Kepros J, Goeschel C: An intervention to decrease
catheter-related bloodstream infections in the ICU. N Engl J Med 2006, 355:2725–2732.
Berenholtz SM, Pronovost PJ, Lipsett PA, Hobson D, Earsing K, Farley JE, Milanovich S, Garrett-Mayer E, Winters BD, Rubin HR, Dorman T, Perl TM: Eliminating catheter-
related bloodstream infections in the intensive care unit. Crit Care Med 2004, 32:2014–2020.
doi:10.1371/journal.pone.0012815.t002
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measurement and valuation of the resources required to
implement the bundle in an Australian context will be complex.
Some of the resources used in implementing the Pronovost et. al.
bundle were shared with existing quality improvement activities
and the concurrent implementation of a comprehensive unit-based
safety program, moreover, the units received substantial admin-
istrative support and mentoring from both the Michigan Health &
Hospital Association Keystone Center for Patient Safety & Quality
and Johns Hopkins University [35]. It is not clear if this kind of
infrastructure or support would be available in Australia and what
the costs of accessing it may be. A final group of costs relating to
the bundle are those incurred by the national campaigns such as
the 100k Lives campaign [3] which promote the use of these
strategies. As the campaigns have already run, they represent sunk
costs which cannot be recovered. As such they are not relevant to
future decision-makers and are excluded from this evaluation.
Evaluating the decision
The cost of implementing a bundle in Australia is unknown. As
such deterministic threshold analyses [36] were used to evaluate
the decision with all parameters characterised as point estimates.
The maximum cost for the bundle was identified at which it would
remain cost-effective assuming it would reduce risk of CR-BSI by
RR CR-BSI 0.34. Given uncertainty about whether the same
reduction in risk would be seen in Australia, we also estimated the
cost-effectiveness of the bundle for different combinations of
effectiveness and cost. For each combination the bundle was
identified as being either cost-saving, cost-effective (i.e. the cost per
QALY was less that AUD $64,000 [37]) or not an efficient
investment (i.e. the cost per QALY was more than AUD $64,000).
Results were plotted on a graph of ‘bundle cost’ against ‘bundle
effectiveness’, and the maximum cost at which the bundle
remained cost-effective was identified for each level of effective-
ness. The threshold costs estimated represent total Australia wide
implementation costs over an 18 month time period.
Recognising that clinicians hold different preferences about the
use of A-CVCs, the threshold analysis was undertaken for three
separate comparisons. First a pair-wise comparison was made
between current practice (where uncoated catheters and a non-
bundled approach to catheter management are used) and the
bundle. This comparison is relevant for decision makers who reject
the use of all A-CVCs. Then a three-way comparison was made:
current practice v. bundle v. CH/SSD catheters. This comparison
is relevant to decision makers prepared to use antiseptic catheters
but who reject the use of antibiotic devices. Finally, a four-way
comparison is made of current practice v. bundle v. CH/SSD
catheters v. MR catheters. This represents the preference of a
decision maker happy to consider use of all technologies.
The results of the baseline analyses enable the decision-maker to
judge whether the bundle is likely to be cost-effective given their
belief about the likely cost and effectiveness of a proposed bundled
intervention, and their current preferences regarding the use of A-
CVCs in infection control. They assume that the decision maker
values the full costs of supplying bed days and the full economic
benefit of generating QALYs. To explore the modelling further we
undertook three sensitivity analyses for each comparison. These
sensitivity analyses represent alternate perspectives for decision
making as valuations placed on QALYs and bed-days by decision
makers may vary.
First, we recalculated the cost-effectiveness threshold under the
assumption that the decision maker was not willing to pay for
QALYs/health benefits and was solely interested in the option
which minimised total costs. Second, we recalculated the cost-
effectiveness threshold assuming the decision maker was willing to
pay for health benefits (up to $64,000 per QALY) but were only
interested in avoiding the variable (or consumable) costs associated
with the extra length of stay and did not value the opportunity cost
of these bed-days (that is, the extra unit capacity obtained). To do
this the valuation for marginal bed-days was changed to reflect the
daily variable costs only, reported in a similar patient population
[38]; this assumes it would be later (less costly) days released by
preventing infection and gives estimates of AUD $362 ICU and
AUD $101 general ward. Third, we recalculated the cost-
effectiveness threshold assuming that the decision-maker was not
willing to pay for either health benefits or the extra unit capacity
released. The interpretation of this scenario is that decision makers
are interested solely in the cash-savings (variable costs avoided) to
the unit.
Results
Figure 2 shows the cost and effectiveness thresholds for the
catheter care bundle compared to uncoated, CH/SSD and MR
catheters.
The area marked ‘‘bundle cost-saving’’ on each graph indicates
combinations of cost and effectiveness at which the bundle reduces
total costs and delivers extra health benefits relative to the
comparator. The area marked ‘‘bundle cost-effective’’ shows
combinations of cost and effectiveness for the bundle at which total
costs increase but the cost per QALY is less than $64,000. Any
combination of cost and effectiveness which places the bundle in
the region marked ‘‘dominated’’ indicates the bundle is not an
efficient investment and the decision-maker should choose the
comparator indicated.
The comparator that should be chosen differs depending on the
preference of the decision maker. Where A-CVCs are not included
in the decision, the preferred option where the bundle is
dominated is to remain with current practice. Where the decision
maker is prepared to use A-CVCs these are the preferred option
should the bundle be dominated as they themselves are cost-
effective relative to remaining with current practice [12]. As the
MR catheter is cost-saving relative to CH/SSD catheters these are
the preferred option in the four-way comparison if the bundle is
dominated.
For all comparisons, the more effective the bundle is, the higher
the cost threshold at which it remains an efficient investment. The
baseline results summarised in Table 3 show the cost at which the
bundle remains cost-effective, assuming, for the Australian
context, that it will deliver a reduction in risk of CR-BSI
equivalent to that seen in Pronovost et al. (RR CR-BSI = 0.34)
[31]. If this effective, it is cost-effective up to a total nationwide 18
month implementation cost of $4,349,730 when compared only to
current practice, $2,287,400 when CH/SSD catheters are
included in the decision and $1,144,465 when MR catheters are
considered a relevant alternative.
Table 3 also shows the maximum cost for at which the bundle
would remain cost-effective assuming it would be able to effectively
eliminate infection (RR CR-BSI = 0.001). Under this assumption
nationwide implementation costs would have to be under $6.6
million when A-CVCs are not considered a relevant option, $4.5
million when CH/SSD catheters are included in the decision and
$3.4 million when MR catheters are included. This represents a
theoretical upper limit on the cost of the bundle. Should
implementation costs exceed this threshold the bundle cannot
represent an efficient use of resources as the cost per QALY will
always exceed $64,000.
The minimum level of effectiveness at which the bundle would
remain cost-effective assuming negligible implementation costs ($1)
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is given in Table 3. Although this assumption is unrealistic as
implementation costs are unlikely to be this low, this represents a
theoretical lower limit on effectiveness below which expenditure
on the bundle will always be an inefficient use of resources. When
compared to current practice and excluding A-CVCs from the
decision, the bundle has the potential to be cost-effective as long as
it is effective and prevents infections (i.e. RR #0.999) However,
when A-CVCs are introduced to the decision, for the bundle to be
cost-effective even with negligible implementation costs, it must
achieve a minimum level of effectiveness of RR =0.684 when
CH/SSD catheters are an option and RR=0.511 when MR A-
CVCs are also being considered. This reflects the fact that the A-
CVCs are themselves effective and cost-saving in reducing risk of
CR-BSI.
The results of the sensitivity analysis are shown in Figure 3. If
decision makers are not willing to pay for QALYs and just want to
minimise total costs, the cost threshold at which the bundle is a
good investment is reduced by around a third relative to the
baseline analysis for all hypothetical levels of effectiveness. If
decision makers place no value on the extra capacity released by
Figure 2. Cost and effectiveness thresholds for a catheter care bundle versus alternative infection control interventions.
doi:10.1371/journal.pone.0012815.g002
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infection control (valuing released bed-days at only the variable
costs saved) then the cost threshold at which the bundle is cost-
effective is halved relative to the baseline analysis. If decision-
makers value neither QALYs nor the opportunity cost of bed-days,
and are only interested in obtaining cash-savings for the unit, the
cost-threshold is reduced by two-thirds for any given level of
effectiveness relative to the baseline analysis. The precise
thresholds for each comparison are given in Table 3.
Discussion
Because clinicians have different preferences for using A-CVCs
we compared the cost-effectiveness of a catheter care bundle to a
baseline (representing use of uncoated catheters and a non-
bundled approach to catheter management) and then to both
CH/SSD and MR catheters in separate analyses. This enables the
decision-maker to judge the likely cost-effectiveness of a bundled
approach given their preference regarding the use of these devices.
The study by Pronovost et al. estimated a bundled approach
was associated with a relative risk of 0.34 (95% CI 0.23, 0.50) [31].
At this level of effectiveness, if clinicians are prepared to use MR
catheters in their clinical practice, the bundle is cost-effective if
nationwide implementation costs over an 18 month period are
below $1.1 million nationally. If costs exceed this then they should
invest in MR A-CVCs as these are cost-effective relative to current
practice. Given that this analysis was based on 46 Level III ICUs,
this represents a maximum 18 month budget per ICU of $24,880.
The uptake of A-CVCs in Australia is very limited [15] despite
evidence about the effectiveness and cost-effectiveness of these
devices. This may be related to clinician concerns about the use of
these devices that is not captured in the economic evidence [12]. If
A-CVCs are not a relevant option then a bundle must cost less
than $4.3 million nationwide, which represents a budget of
$94,559 per ICU. If costs exceed this threshold then the units
should remain with current practice.
The economic outcomes from infection control are summarised
in terms of QALYs and total costs. The main component of total
costs is the opportunity cost assigned to each bed-day released by
infection control [39], which is its value in being able to use it to
treat another patient. Our baseline analysis assumed that decision-
makers were prepared to pay $64,000 per QALY and $1032 per
ICU bed-day. However, these figures represent preferences which
Table 3. Cost and effectiveness thresholds for a catheter care bundle under different perspectives.
Scenario Baseline
No value given to
QALYs
No value given to
extra unit capacity
Interested only
in cash-savings
Willingness to pay for a QALY $64,000 $0 $64,000 $0
Value for an ICU bed-day $3021 $3021 $362 $362
Value for a ward bed-day $843 $843 $101 $101
Comparisons
Bundle v. current practice
choice if bundle dominated Current practice Current practice Current practice Current practice
minimum RR for bundle to dominate 0.999 0.999 0.999 0.999
cost threshold at RR = 0.34 (estimate
from Pronovost et al.)
$4,349,730 $2,801,690 $2,020,600 $472,550
cost threshold at RR = 0.001 (theoretical
maximum)
$6,646,520 $4,285,050 $3,087,550 $722,100
Bundle v. CH/SSD catheters v. current practice
choice if bundle dominated CH/SSD cost-saving CH/SSD cost-saving CH/SSD cost-saving CH/SSD cost-
saving
minimum RR for bundle to dominate 0.684 0.697 0.712 0.883
cost threshold at RR = 0.34 (estimate
from Pronovost et al.)
$2,287,400 $1,529,810 $1,147,560 $389,970
cost threshold at RR = 0.001 (theoretical
maximum)
$4,584,200 $3,013,160 $2,214,500 $639,500
Bundle v. MR catheters v. CH/SSD catheters v. current practice
choice if bundle dominated MR cost-saving MR cost-saving MR ICER $16,717/qaly CH/SSD cost-
saving
minimum RR for bundle to dominate 0.511 0.579 0.652 0.883
cost threshold at RR = 0.34 (estimate
from Pronovost et al.)
$1,144,465 $1,025,205 $965,030 $389,970
cost threshold at RR = 0.001 (theoretical
maximum)
$3,441,280 $2,508,550 $2,031,980 $639,500
All cost thresholds represent nationwide implementation costs over an 18mth period. Costs per ICU can be obtained by dividing each figure by 46 e.g. given RR = 0.34
the cost threshold per ICU for the bundle relative to no intervention equals $4,349,730/46 = $94,559.
It is important to note that when both CH/SSD and MR catheters are being considered, the MR catheters are the preferred option where the bundle is dominated for all
scenarios except where health benefits are valued at zero and bed-days only at the value of variable costs. Under this scenario where the bundle is dominated the MR
catheters are not cost-effective as the cost per QALY exceeds $64,000 and it is the CH/SSD catheters that are preferred, hence the shift in the threshold seen in Figure 3c.
doi:10.1371/journal.pone.0012815.t003
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may vary according to the perspective of the decision-maker. Our
baseline valuations represent a broad healthcare perspective. A unit
manager operating on a fixed budget may hold different values for
these outcomes. The results of our sensitivity analysis show that the
cost threshold at which the bundle remains the preferred choice
drops by a third if no value is placed on QALYs and halves if no
value is given to the opportunity cost of bed-days. Infection control
is often referred to as being ‘‘cost-saving’’. Our final sensitivity
analysis highlights how this term should not be confused with ‘‘cash-
saving’’. If a decision-maker is concerned only with reducing unit
cash expenditures, and places no economic value on QALYs or
extra bed days (i.e. the capacity to treat new patients), then the cost
threshold for the bundle relative to no intervention (given a RR
=0.34) drops from $4.3 million to $472,550.
Infection control interventions are often cost-saving, but this
term can be somewhat misleading, as most infection control
interventions are unlikely to produce cash savings for the unit into
which they are introduced and, in fact, the opposite may occur.
The cost-savings these infection control interventions achieve are
better thought of as opportunity costs avoided, the main
component of which is the value assigned to the bed-days released
by infection control. Most of the costs of hospital care (84%) are
Figure 3. Cost and effectiveness thresholds for a catheter care bundle under different decision making perspectives.
doi:10.1371/journal.pone.0012815.g003
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fixed in the short term [40], and, as the fixed running costs of the
ICU cannot be recovered, they will not alter with changes to rates
of infection [41,42]. Units which expend more of their funds on
infection control are unlikely to see cash returns on this
investment. Although the extra capacity enables the treatment of
more patients, the initial review, diagnosis and establishment of
another patient is costly in terms of consumables and staff time
which will drive up variable costs. Overall, the healthcare system
as a whole will become more efficient, and average cost per patient
will fall, but this increase in the variable costs needed to treat these
extra patients may result in an increase to total costs in the
healthcare system [5]. Focusing on the economies resulting from
improving the use of fixed costs, rather than focusing on achieving
a reduction in expenditure is likely to be a better approach to
justifying and sustaining investment in infection control [43], but
even so, decision-makers at both the local (unit) level and the level
of the healthcare system, be it centralised or de-centralised, must
be prepared to invest resources in infection control to see this
efficiency improvement.
The likelihood of being able to implement a catheter care
bundle in Australia for less than $4.3 million is unclear. It would
depend upon the resources required for implementation (the main
component of which is likely to be personnel and staff time), the
degree to which these resources would be centralised rather than
spread (and possibly duplicated) across individual States/Territo-
ries and/or hospital sites, the value of these resources and how
often these costs would have to be incurred. A budget of $94,559
per ICU would pay for a coordinator in each site but probably
little else. Moreover, although a $4.3 million dollar catheter care
bundle initiative would be cost-effective, it would represent a
substantial investment. For decision-makers facing finite budgets,
any increases to present levels of funding for infection control
activities will necessitate decisions about from which other area of
healthcare these extra funds should be sourced. An investment of
this magnitude would require careful consideration to ensure that
other important, effective and efficient services were not
displaced. Given the announcement of a $4 million investment
in the National Hand Hygiene Initiative in May 2009, it may be
that there will not be the funds to support another large scale
initiative aimed at, what may be perceived to be, a very similar
healthcare objective. On the other hand the development of a
national infrastructure for rolling out infection control initiatives
may drive the cost of subsequent initiatives down as spare
capacity in existing personnel and resources could be utilised.
This would provide further support for implementing a catheter
care bundle.
There are a number of limitations to this analysis of the cost-
effectiveness of a bundled behavioural intervention for preventing
CR-BSI, and the use of this information for infection control
decision making. Evidence for a bundled behavioural intervention
to prevent CR-BSI suggests that this approach may be highly
effective [30]. However, the evidence is undermined by problems
in the design and conduct of the trials, and as all studies used
slightly different variants of the bundle it is difficult to predict
whether a comparable reduction in risk would be achievable in
Australia. We were unable to estimate the cost of this type of
intervention in an Australian context because it was unclear what
the full resource requirements are for the implementation of
bundle, and what the value of these would be. As such we
undertook a threshold analysis to identify the cost and effectiveness
thresholds at which a hypothetical bundle would be cost-effective
relative to no investment in infection control and the thresholds at
which it would dominate the use of A-CVCs. This approach places
the onus on others to make a judgement about levels of cost and
effectiveness of the bundle which limits its ability to guide efficient
decision making. A high quality study that estimates the costs of
implementing a bundle would increase the usefulness of this
modelling.
As the estimates of effectiveness for all interventions are
measured in relative units, the specific estimates of cost-
effectiveness for the A-CVCs and the cost and effectiveness
thresholds obtained for the bundle relate specifically to a baseline
infection rate of 2.5%. For decision-makers in settings where the
infection rate differs significantly from this value, care should be
taken in interpreting these results and caution used in basing
decisions on specific thresholds. Although this difference may not
change the relative ordering of the interventions, where initial
rates of infection are higher the precise cost threshold at which the
bundle is cost-effective for any given level of effectiveness will be
higher, and where infection rates are lower, the threshold will be
lower.
It is also likely given the broad range of outcomes decision
makers consider when deciding on the adoption of a new
technology [44,45] that not all relevant costs and benefits have
been captured in this evaluation. There are a number of
potential negative externalities that can result from the use of A-
CVCs [13,14], and several positive ones that may be delivered by
a catheter care bundle [9,34] that have not been included. This
evaluation did not include less tangible benefits to reduced
infection rates, such as increases to clinical morale and public
confidence in the healthcare system demonstrated by the
national campaigns to reduce rates of CR-BSI [3] and forming
part of the rationale for the introduction of the Deficit Reduction
Act in the United States [4]. Valuing these outcomes would be
difficult to achieve and these concerns may be best considered in
a decision-making framework alongside, rather than subsumed
into, the economic evidence. Excluding these costs and benefits
from the analysis does not result in them being excluded from the
adoption decision. Instead, it leaves decision-makers to consider
them implicitly, creating the potential for these concerns to be
assigned arbitrary values based on the potential for bad press or
political backlash. Their inclusion would improve the represen-
tation of the economics of preventing infection and more
accurately reflect the trade-offs being made by decision-maker
which may help prevent this reactionary approach to decision-
making.
Conclusion
Estimates of the cost of a catheter care bundle should include
the costs of monitoring, education and clinical leadership activities,
as well as the cost of the consumables used in the care practices
included in the bundle. If clinicians are prepared to use
antimicrobial catheters in their clinical practice, a bundle which
achieves a relative risk of catheter-related bloodstream infection of
0.34 is cost-effective if nationwide implementation costs over an 18
month period are below $1.1 million nationally, a budget of
$24,880 per intensive care unit. If costs exceed this then
minocycline and rifampicin-impregnated catheters should be used.
If antimicrobial catheters are not a relevant option then a bundle
must cost less than $4.3 million nationally, which represents a
budget of $94,559 per unit. If costs exceed this threshold then the
units should remain with current practice, defined here as
uncoated catheters and a non-bundled approach to catheter
management. These thresholds assume that decision makers are
willing to pay for both health benefits obtained and bed-days
released by infection control. If no economic value is placed on the
bed-days released by infection control then these cost thresholds
are halved, whilst if no economic value is placed either the bed-
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days or the health benefits gained through preventing infection,
these cost-thresholds are reduced by two-thirds. Rather than
anticipating cash-savings decision makers should be prepared to
invest resources in infection control to gain efficiency improve-
ments in the intensive care unit.
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